Biotech major Biocon has increased its gross Research and Development (R&D) expenditure by nearly 15 per cent. The company, which has R&D as a key focus, saw its gross R&D spends at Rs 54 crore, which is about 10 per cent of the company’s biopharma revenues and was Rs 7 crore over and above its gross R&D spend during the corresponding quarter of the previous year. Of the gross R&D spend of Rs 54 crore, the company’s net R&D spend was Rs 31 crore. Moreover, the company capitalised around Rs 16 crore of the development costs and Rs 7 crore came from the deferred revenues from the annulled deal with Pfizer.
The company has reported 10.06% rise in its consolidated net profit after taxes & Minority interest at Rs 102.91 crore for the quarter as compared to Rs 93.50 crore for the same quarter in the previous year. Total income has increased by 2.59% at Rs 741.95 crore for quarter under review as compared to Rs 723.17crore for the quarter ended June 30, 2013.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1665.25 |
| Dr. Reddys Lab | 1220.75 |
| Cipla | 1232.90 |
| Zydus Lifesciences | 928.85 |
| Lupin | 2311.75 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: